All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
#EHA2024: Longer-term follow-up, patient outcomes, and real-world findings in multiple myeloma
Catch up with our live social media coverage of the latest developments in longer-term follow-up, patient outcomes, and real-world findings in multiple myeloma from the European Hematology Association (EHA) 2024 Congress.
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Congress, we have collated our social media coverage. Catch up with our live social media relating to longer-term follow-up, patient outcomes and real-world findings in multiple myeloma here.
CONGRESS | POSTER | #EHA2024 | Julia Mersi presented findings on the spectrum and duration of infectious complications in patients treated with BCMA- and GPRC5D-targeted immunotherapies in MM, N=137. Different patterns of frequency and duration were observed. #mmsm #myeloma… pic.twitter.com/FjmxGP2qjZ
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Katarina Uttervall discusses longer-term follow-up of patients with RRMM receiving prophylactic tocilizumab (n=24) for reduction of CRS in the phase I/II MAJESTEC-1 study. Prophylactic tocilizumab reduced Grade 1/2 CRS from 72.1 to 25%. #mmsm… pic.twitter.com/xPkoumpkNL
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Mohamad Mohty @Mohty_EBMT shares long-term survival outcomes from the phase II MagnetisMM-3 study of elranatamab in patients with RRMM, N=123. ORR remained at 61%, with median DoR not reached. #mmsm #myeloma #MedicalCongress pic.twitter.com/FDjz9FIgSb
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Leo Rasche @RascheLeo shares long-term efficacy and safety results from the phase I/II MONUMENTAL-1 study of talquetamab (TAL) in patients with RRMM, N=375. ORR ≥70% in TCR-naïve and 67% in prior TCR. #mmsm #myeloma #MedicalCongress pic.twitter.com/n6udlYNyn3
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Sharlene Dong @sharlenedong discusses real-world carfilzomib (K) prescribing patterns and outcomes for patients with RRMM, N=2420. Once-weekly K dosing is now SoC; higher doses/frequencies were not associated with improved outcomes vs weekly K… pic.twitter.com/fLC5636zCO
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Saad Usmani @szusmani @MSKCancerCenter shares findings from a real-world schedule de-escalation of teclistamab (TEC) in patients with RRMM, N=86. Despite a high-risk patient population, TEC demonstrated a 61% ORR, comparable to MajesTEC-1. #mmsm… pic.twitter.com/d7I5iDRSf1
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS #EHA2024 | Presidential Session | @BrunoPaiva_UNA @ClinicaNavarra @CIMA_unav @idisnanavarra provides an insightful discussion on innovative tools for disease monitoring in #MultipleMyeloma. They discuss current disease monitoring strategies and potential future… pic.twitter.com/bQpDHiVImE
— Multiple Myeloma Hub (@MM_Hub) June 16, 2024
CONGRESS #EHA2024 | Sarah Cayla, @univ_paris_cite highlights an analysis of outcomes of patients with R/R MM following early progression after ide-cel therapy using the DESCAR-T database. Patients who relapsed after ide-cel had poor outcomes, even with the use of bispecific… pic.twitter.com/BRugytJne0
— Multiple Myeloma Hub (@MM_Hub) June 16, 2024
CONGRESS #EHA2024 | Philippe Moreau, @CHUnantes presents long-term outcomes from the phase III CASSIOPEIA trial of D-VTd followed by DARA maintenance in transplant-eligible patients with NDMM. D-VTd induction and consolidation plus DARA maintenance resulted in the most pronounced… pic.twitter.com/WoZ4aEgQBW
— Multiple Myeloma Hub (@MM_Hub) June 15, 2024
Your opinion matters
47 votes - 9 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox